Psychiatry · AntipsychoticRegulatory Approvalregulatorymid-term

FDA Grants Supplement Approval for Lurasidone Hydrochloride by Amneal Pharmaceuticals

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Amneal Pharmaceuticals9 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 12:31:27 PM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of the supplemental application for Lurasidone Hydrochloride by Amneal Pharmaceuticals is significant as it may strengthen their competitive position in the antipsychotic market. Portfolio teams need to evaluate the potential impact on market share and pricing strategies in response to this regulatory development. Regulatory context from FDA (FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies for antipsychotic medications. The strongest clinical anchor is Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. In Psychiatry · Antipsychotic, 7 regulatory and 0 competitive items passed relevance filtering for Amneal Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from This approval may enhance Amneal's position in the antipsychotic market, potentially impacting competitors with similar products..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (lurasidone hydrochloride). The approval indicates compliance with FDA standards, which may set a precedent for future applications in the antipsychotic category.

Key Risks

Elevated medium regulatory exposure for Amneal Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This approval could lead to increased market share for Amneal, influencing pricing dynamics and competitive positioning among antipsychotic products.
Upside for Amneal Pharmaceuticals may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the implications of this approval on market share and pricing strategies for antipsychotic medications.

What Would Change This Assessment

This becomes more urgent if Monitor for market launch details and any subsequent competitive responses from other antipsychotic manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (lurasidone hydrochloride)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — RILPIVIRINE HYDROCHLORIDE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of The Perfusion Index and The Surgical Pleth Index in Detecting The Effectiveness of Caudal Block in Pediatrics
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safe, Effective and Cost-Effective Oxygen Saturation Targets for Children and Adolescents With Respiratory Distress: Randomized Controlled Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

No evidence in this category.

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Amneal Pharmaceuticals
Lurasidone Hydrochloride
competitors in psychiatry

Commercial impact

medium

This approval could lead to increased market share for Amneal, influencing pricing dynamics and competitive positioning among antipsychotic products.

Regulatory impact